In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Ignyta, Inc.

https://ignyta.com/

Latest From Ignyta, Inc.

Finance Watch: Erasca Raises $200m As VC Mega-Rounds Continue

Private Company Edition: In addition to Erasca’s big series B round, Mabwell reportedly brought in $278m. Also, Kurma, Venrock and Section bring the number of new VC funds in April to eight, raising $5.89bn, and former AveXis execs launched the new gene therapy venture Taysha.

Financing Innovation

Big Pharma BD Execs Tell Start-Ups: Don’t Be Afraid To Ask Us For Help

Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.

StartUps and SMEs Deals

Roche Keeps Eye On The Science As Asia Innovation Emerges

Roche's main consideration when partnering is to "access great science" regardless of location. More of this is expected to come out of Asia, its global partnering head tells Scrip.

Asia Pacific Innovation

Boundless Bio Launches With $46m And Novel Oncology Focus On Extrachromosomal DNA

Former Ignyta executive Zachary Hornby wasn't wowed by immuno-oncology pitches when looking for his next cancer drug development company, but was intrigued by ecDNA research at UCSD, which also could generate a tumor agnostic approach.

StartUps and SMEs Financing
See All

Company Information

  • Other Names / Subsidiaries
    • Actagene Oncology, Inc.
    • NexDx, Inc.
UsernamePublicRestriction

Register